BioCryst (Nasdaq: BCRX) has completed its analysis of results from a study of a low dose of BCX5191 in chimpanzees ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE